Form 4: Oric Pharma Director Granted Stock Options

Oric Pharmaceuticals director Mardi Dier was granted 40,000 stock options with an exercise price of $8.17, vesting monthly over a year.

Summary

• Mardi Dier, a Director of Oric Pharmaceuticals, Inc. (ORIC), was granted 40,000 stock options.
• The transaction date for this grant was January 2, 2026.
• The exercise price for these stock options is $8.17 per share.
• The options will vest at a rate of 1/12th of the shares on each one-month anniversary of January 2, 2026.
• The expiration date for these stock options is January 1, 2036.
• Following this transaction, Mardi Dier beneficially owns 40,000 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: Routine grant of stock options to a director, aligning their interests with shareholders, which is generally viewed as a neutral to slightly positive event.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term company performance.
• Equity compensation is a standard practice for attracting and retaining qualified board members.

Future Outlook

The stock options granted to Director Mardi Dier will vest monthly over a one-year period starting January 2, 2026, indicating a future increase in her beneficial ownership of common stock as options become exercisable.

Industry Context

The grant of stock options to a director is a common form of executive and board compensation in the biotechnology and pharmaceutical industries, aiming to align leadership incentives with long-term shareholder value creation. This practice is consistent with typical compensation structures for publicly traded companies.

Comparison to Industry Standards

• Equity compensation, such as stock options, is a standard component of director remuneration across the U.S. public company landscape, particularly in growth-oriented sectors like biotechnology.
• The vesting schedule of 1/12th monthly over a year is a common approach to encourage retention and sustained performance, similar to practices observed at comparable biotech firms like Gilead Sciences or Amgen for their non-employee directors.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders, potentially leading to better long-term decision-making focused on increasing share value.
• Management: Reinforces the company's compensation strategy for its leadership.

Next Steps

• The stock options will begin vesting on a monthly basis starting January 2, 2026, over a one-year period.

Key Dates

Keywords

Oric Pharmaceuticals, ORIC, Stock Options, Insider Transaction, Director Compensation, Equity Grant, Form 4, SEC Filing